Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Single Country / Region · Innovator

MAPTX Alternatives & Equivalents

Ticker MAPTX · Since 1994-09-12 · · Holdings as of Jun 30, 2026

Expense ratio
1.22%$122/yr per $10k
5-yr return
−0.6%annualized
1-yr return
+30.1%as of Dec 2025
Net assets
$889.3Mall share classes
Holdings
66

Bottom line

What is similar to MAPTX?

We compared MAPTX's top holdings against every single country / region fund. The closest match is ASIA (Matthews Pacific Tiger Active ETF), with about 79% portfolio overlap. The cheapest similar fund is XCEM at 0.16% vs 1.22% for MAPTX. Equivalents exist at iShares, T. Rowe Price.

MAPTX equivalent at each fund company

Useful if your 401(k) or brokerage only offers one family's funds — for example, the Fidelity or Schwab equivalent of MAPTX.

Best overlap match per family (minimum 50% overlap)
FamilyEquivalentExpense ratio5-yr returnOverlap
iShares equivalent of MAPTXAIA iShares Asia 50 ETF0.5%+4.7%59%
T. Rowe Price equivalent of MAPTXPRASX T. Rowe Price New Asia Fund1.03%+0.7%56%

Funds most similar to MAPTX

Ranked by top-holdings overlap
FundFamilyExpense ratio5-yr returnOverlap
ASIA Matthews Pacific Tiger Active ETFInnovator0.79%—79% Compare
MSEIX AMG Veritas Asia Pacific FundAMG0.93%+1.7%61% Compare
AIA iShares Asia 50 ETFiShares0.5%+4.7%59% Compare
FLAX Franklin FTSE Asia ex Japan ETFFranklin Templeton0.19%+3.9%59% Compare
PRASX T. Rowe Price New Asia FundT. Rowe Price1.03%+0.7%56% Compare
XCEM Columbia EM Core ex-China ETFColumbia Threadneedle0.16%+7.4%54% Compare
AAXJ iShares MSCI All Country Asia ex Japan…iShares0.72%+1.5%52% Compare
MINV Matthews Asia Innovators Active ETFInnovator0.79%—44% Compare
FHKCX Fidelity China Region FundFidelity0.91%+3.6%42% Compare
MITEX Matthews Asia Innovators FundInnovator1.13%−0.4%41% Compare

Overlap = share of the two funds' top-25 holdings (by weight) that they have in common, from SEC Form N-PORT. Funds that hold other funds are matched by benchmark when holdings aren't comparable.